The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Trending   »  Galera Therapeutics Inc. (GRTX) Stock: Evaluating ...

Galera Therapeutics Inc. (GRTX) Stock: Evaluating the Annual Growth

In the past week, GRTX stock has gone down by -1.45%, with a monthly decline of -17.84% and a quarterly plunge of -93.76%. The volatility ratio for the week is 5.10%, and the volatility levels for the last 30 days are 6.70% for Galera Therapeutics Inc. The simple moving average for the past 20 days is -8.19% for GRTX’s stock, with a -91.03% simple moving average for the past 200 days.

Is It Worth Investing in Galera Therapeutics Inc. (NASDAQ: GRTX) Right Now?

compared to its average ratio and a 36-month beta value of 1.91. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price point forecasted by analysts for Galera Therapeutics Inc. (GRTX) is $0.35, The public float for GRTX is 39.83M, and currently, short sellers hold a 6.09% ratio of that float. The average trading volume of GRTX on September 19, 2023 was 2.59M shares.

GRTX) stock’s latest price update

Galera Therapeutics Inc. (NASDAQ: GRTX)’s stock price has increased by 1.11 compared to its previous closing price of 0.19. However, the company has seen a -1.45% decrease in its stock price over the last five trading sessions. Benzinga reported 2023-09-06 that The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Analysts’ Opinion of GRTX

Many brokerage firms have already submitted their reports for GRTX stocks, with Piper Sandler repeating the rating for GRTX by listing it as a “Neutral.” The predicted price for GRTX in the upcoming period, according to Piper Sandler is $0.50 based on the research report published on August 10, 2023 of the current year 2023.

GRTX Trading at -85.89% from the 50-Day Moving Average

After a stumble in the market that brought GRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.69% of loss for the given period.

Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 5.10%, as shares sank -13.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -93.49% lower at present.

During the last 5 trading sessions, GRTX fell by -1.45%, which changed the moving average for the period of 200-days by -88.37% in comparison to the 20-day moving average, which settled at $0.2062. In addition, Galera Therapeutics Inc. saw -87.20% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GRTX starting from Bachleda Mark, who purchase 11,000 shares at the price of $2.25 back on Mar 16. After this action, Bachleda Mark now owns 11,000 shares of Galera Therapeutics Inc., valued at $24,717 using the latest closing price.

Degnan Chris, the Chief Financial Officer of Galera Therapeutics Inc., purchase 10,000 shares at $1.96 during a trade that took place back on Mar 13, which means that Degnan Chris is holding 10,000 shares at $19,593 based on the most recent closing price.

Stock Fundamentals for GRTX

The total capital return value is set at -101.58, while invested capital returns managed to touch -123.75. Equity return is now at value 67.40, with -139.40 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.


To put it simply, Galera Therapeutics Inc. (GRTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Should You Invest in BP p.l.c. (BP) Now?

BP p.l.c. (NYSE: BP) has a higher price-to-earnings ratio of 5.78x compared to its average ratio, and the 36-month beta value for BP is at